Results 211 to 220 of about 98,491 (346)

Synthesis of Bispecific Conjugates by ADP‐Ribosyl Cyclases

Advanced Science, EarlyView.
Genetic fusion of a CD38 enzymatic domain to antibody scaffolds allows site‐specific conjugation of small‐molecule ligands. Using this approach, a PSMA ligand DUPA is conjugated with an anti‐human CD3 Fab antibody. The resulting bispecific anti‐CD3‐DUPA conjugate facilitates recruitment and activation of cytotoxic T cells against PSMA‐expressing ...
Sunny H. Kim, Arshad J. Ansari, Lei Zhang, Guoyun Kao, Thuc Oanh Hoang, Zeyu Zhang, Srinivasarao Singireddi, Benjamin B. Katz, Yong Zhang   +8 more
wiley   +1 more source

Diagnostic accuracy of interferon-gamma release assay and mucosal-associated invariant T cells in spinal tuberculosis. [PDF]

Sci Rep
Mekariya K, Ayutthaya PSN, Naowanirut A, Wongsa A, Tassaneetrithep B, Tantibhedhyangkul W, Ngamskulrungroj P, Muangsomboon S, Cheiwvit P, Wilartratsami S, Luksanapruksa P, Danchaivijitr N, Boonchai K, Rattanatanasarn A, Ruangchainikom M.   +14 more
europepmc   +1 more source

A Programmable Nanoreactor Orchestrates Cascade of DNA Sensing to Amplify cGAS‐STING Activation for Cancer Immunotherapy

Advanced Science, EarlyView.
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang, Yiwei Tian, Feiyu Zhao, Yue Han, Kongshuo Ma, Linna Hai, Kaiqing Yun, Yueyang Zhao, Siqi Zhang, Ziyi Zhang, Yuxuan Peng, Kuan Hu, Jing Zhong, Bai Xiang, Zhaohui Wang   +14 more
wiley   +1 more source

Engineered Small Extracellular Vesicles Targeting Tumor‐Associated Endothelial Cells to Effectively Remodel the Glioma Microenvironment

Advanced Science, EarlyView.
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu, Feiyang Xu, Zhiming Zheng, Xiaodan Yang, Fang Yang, Pei Liu, Yuankun Chen, Yunshu Yang, Junli Zhao, Peiyan Yang, Xiaojing Zheng, Xiaohong Sun, Ping Mao, Qinwen Mao, Hao Guan, Haibin Xia, Weifeng Zhang, Dan Xiao   +17 more
wiley   +1 more source

A multiplex Mtb-specific FluoroSpot assay measuring IFNγ, IL-2, and TNF-secreting cells can improve accuracy and differentiation across the tuberculosis spectrum. [PDF]

J Clin Microbiol
Folkesson E, Foroogh F, Kleberg L, Kjellgren V, Jakobsson M, Grunewald L, Hellberg J, Ryberg J, Maher Z, Silva CS, Gower MS, Grönlund H, Correia-Neves M, Makower B, Källenius G, Bruchfeld J, Sundling C.   +16 more
europepmc   +1 more source

Interferon-Gamma Release Assays and Pediatric Public Health Tuberculosis Screening: The San Francisco Program Experience 2005 to 2008.

Journal of the Pediatric Infectious Diseases Society, 2016
J. Grinsdale, S. Islam, O. C. Tran, Christine S. Ho, Julie Higashi, Julie Higashi, S. Francisco   +6 more
semanticscholar   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Evaluating Canada's initiative of enhanced screening for tuberculosis infection in migrants: Implementation lessons from Alberta. [PDF]

Can Commun Dis Rep
Heffernan C, Jamro A, Egedahl ML, Long R.   +3 more
europepmc   +1 more source

Potent and Selective IGF‐IIR‐Recruiting Bifunctional Molecules for Targeted Lysosomal Degradation of Extracellular and Membrane Proteins

Advanced Science, EarlyView.
Lysosome‐targeting chimeras (LYTACs) enable degradation of extracellular and membrane proteins via lysosomal trafficking. We report a novel IGF‐II mutant (Del1–7, Y27L) that selectively engages IGF‐IIR while avoiding IGF‐IR and IR‐A. mutIGF‐II–based LYTACs enhance target internalization and degradation and support a genetically encodable, all‐protein ...
Yuan Zhao, Yaxian Liao, Pengyun Li, Regina Stasser de Gonzalez, Xuankun Chen, Nicholas S. Nieto, Florence M. Brunel, Nick Cox, Joseph Stock, Matthew McHenry, Guangsen Fu, Penghsuan Huang, Wenxin Wu, Deqin Cai, Lingjun Li, Alexander N. Zaykov, Weiping Tang   +16 more
wiley   +1 more source

A Case of Advanced Urothelial Carcinoma Requiring Treatment Following a Positive Interferon-Gamma Release Assay Prior to Avelumab Administration. [PDF]

IJU Case Rep
Odagiri Y, Hiyama Y, Ishida U, Nishiyama N, Yamamoto Y, Kitamura H.   +5 more
europepmc   +1 more source